Stop Racing to the Bottom: The Generic Drug Strategy That Builds Real Competitive Advantage
How patent intelligence, regulatory mastery, and manufacturing technology are separating the winners from the commoditized in a $700 billion market […]
Compounding Pharmacies vs. Drug Patents: The Complete IP Battleground Guide for Pharma Strategists
A technical deep-dive for IP counsel, 503B portfolio managers, brand lifecycle teams, and institutional investors tracking the $10.93B compounding market.
Method-of-Use Patents: The Definitive Analyst’s Guide to the New Front Line in Generic Drug Litigation, IP Valuation, and Strategic Defense
1. Why Method-of-Use Patents Now Control More Revenue Than Compound Patents A structural shift has occurred in pharmaceutical patent litigation
Generic Drug Patent Disputes: The Complete Analyst’s Guide to Paragraph IV Challenges, Patent Thickets, and Hatch-Waxman Litigation Strategy
I. Executive Summary The U.S. pharmaceutical patent system is not a passive legal framework. It is an engineered adversarial machine,
Drug Patent Expiry Forecasting: The Definitive 3-Year Drug Spend Playbook for Payers, PBMs, and Portfolio Managers
A comprehensive technical guide to building event-driven pharmaceutical cost forecasts using patent expiration data, FDA exclusivity calendars, Paragraph IV litigation
Generic Drug Portfolio Strategy: The Complete Guide to Finding High-Margin Opportunities Before Your Competition Does
The global generic drug market will cross $700 billion by the early 2030s. Individual companies inside it are getting crushed.
Drug Patent Alpha: How Pharma IP Data Predicts Stock Performance Before the Market Does
1. Why the Patent Portfolio Is the Real Balance Sheet A company’s income statement tells you what it earned last
Drug Patent Alpha: How Pharma IP Data Predicts Stock Performance Before the Market Does Read Post »
Paragraph IV Playbook: How NCE-1 Filing Data Predicts Patent Cliffs Before Wall Street Does
Section 1: The Hatch-Waxman Architecture: Why Conflict Is a Feature, Not a Bug Most people who cover pharmaceutical equities understand
Generic Drug Formulation: The Complete Technical and Strategic Playbook From Pre-Formulation Science to Patent Thicket Navigation, Bioequivalence Mastery, and Biosimilar Development
Generic drug development has a public relations problem. The phrase ‘generic drug’ suggests a simple act of copying, the pharmaceutical
